Monoclonal antibodies monospecific to single-chain urokinase-type plasminogen activator (scu-PA).

Until now, single-chain urokinase-type plasminogen activator (scu-PA) could not be distinguished from urokinase (UK) by immunological methods. Therefore, in our study monoclonal antibodies (mAbs) specific for scu-PA were raised in mice. These mAbs proved to discriminate between scu-PA, UK and plasmin-activated scu-PA.

Determination of oxprenolol and its glucuronide metabolite in plasma and urine using high-performance liquid chromatography.

A HPLC assay is presented for the determination of oxprenolol (1) and its glucuronic acid conjugate (2) in human plasma and urine. The procedure employs a selective re-extraction using alprenolol (3) as the internal standard, followed by reversed-phase chromatography and UV-detection. The minimal detectable concentration is 10 ng/ml in plasma and 50 ng/ml in urine, using 1.

Determination of antileukemic diimidazolinyl compounds in plasma of experimental animals by high-performance liquid chromatography.

A method is reported for the determination of the fluorescent, antileukemic diimidazolinyl compounds 261/96(1). 253/152(2) and 272/131(3) in plasma. HPLC is performed on a RP-2 10 microns column with a mobile phase of methanol/water (1:1, v/v), to which 0.

Determination of sotalol in human body fluids for pharmacokinetic and toxicokinetic studies using high-performance liquid chromatography.

A sensitive, reliable and discriminating assay method is reported for the determination of sotalol (4-(1-hydroxy-2-isopropylaminoethyl)methanesulfonanilide) in human plasma and urine. The assay procedure has been successfully used during pharmacokinetic studies in healthy volunteers and patients as well as during toxicokinetic analysis. For sample preparation the internal standard atenolol was added to the specimen which was then extracted with n-pentanol-chloroform (1/3) at pH 9.

Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?

The pharmacokinetics of disopyramide was studied in 15 patients with renal dysfunction (4 with pyelonephritis, 7 with glomerular nephritis and 4 with interstitial nephritis). The elimination rate constant of unbound disopyramide was 0.094 h-1 and CLu/f (unbound clearance divided by bioavailability) was 245 ml/min.

Determination of fluorescent diamidines in plasma of experimental animals by high-performance liquid chromatography.

The fluorescent diamidines (E)-2,2'-vinylenedi-1-benzo [b] furane-5-carboxamidine dihydrochloride (I) and 2-[2-(6-amidinoindole-2-yl)-(E)-vinyl]-1-benzofurane-5-ca rbo xamidine dihydrochloride (II) were determined in the plasma of experimental animals by high-performance liquid chromatography with a mobile phase of methanol-water (60:40, v/v) containing 0.005 M octanesulphonic acid and 0.003 M dimethyloctylamine.

Bioavailability of disopyramide in normal volunteers using unbound concentration.

The pharmacokinetics of disopyramide were determined in 10 healthy volunteers after a 300 mg oral dose and again after a 2 mg/kg i.v. dose.

Determination of fluorescent trypanocidal diamidines by quantitative thin-layer chromatography.

The fluorescent trypanocidal diamidines 2-(4-amidinophenyl)indole-6-carboxamidine dihydrochloride (I, DAPI), 2-(4-amidinophenyl)benzo[b]thiophene-6-carboxamidine dihydrochloride (II) and 2-(4-amidinophenyl)-1-benzofurane-5-carboxamidine dihydrochloride (III) were determined in plasma, urine, faeces and tissues of experimental animals using quantitative thin-layer chromatography. Samples were extracted with n-octanol after addition of sodium hydroxide and subsequently re-extracted into 0.1 M hydrochloric acid.

Pharmacokinetics of tocainide in patients with severe renal failure.

The plasma levels of tocainide have been followed after oral administration of 600 mg p.o. to 20 patients with renal failure due to various causes, and to 8 healthy controls.

Pharmacokinetic properties of antileukemic and trypanocidal compounds with amidino and imidazolinyl groups.

The pharmacokinetics of a series of heterocyclic compounds substituted with amidino or imidazolinyl groups and showing trypanocidal and antileukemic activity has been studied in mice and rats using radiolabelled material and newly developed HPLC techniques. Trypanocidal compound 261/115 (2-Amidino-indole-6-carboxamidine) showed species differences in mice and rats, however, in mice no differences were detected after i.p.